PNTG Pennant (PNTG) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-health services · CIK 0001766400
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
102
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $110.2K priced
What the filings say about PNTG
Insiders, 180 days
-$690.1K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$272.4K
3 notices
Pennant insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Pennant Group, Inc. insiders sold a net $690.1K of stock across 41 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.2% of the 15,106 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Clinical Officer Steik Jason Paul sold about $53.7K of PNTG on Aug 6, 2026; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 28, 2025.
- The trade is 7.6% of the 18,401 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC and Corp Secy Cheney Kirk Sterling sold about $53.7K of PNTG on Aug 6, 2026; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 10, 2026.
- The trade is 4.3% of the 99,544 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Guerisoli Brent sold about $165.1K of PNTG on Aug 6, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jul 7, 2026.
- The trade is 3.0% of the 103,829 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Guerisoli Brent sold about $131.3K of PNTG on Jul 10, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 22, 2026.
- The trade is 3.1% of the 100,740 shares held after it.
- 2 other insiders sold within 30 days.
- 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Guerisoli Brent sold about $128.2K of PNTG on Jul 7, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$690.1K over 180 days
-$272.4K over 90 days
more than 57% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
102 funds bought in last quarter
below 61% of Healthcare Services
Revenue
+36.3% year over year
more than 85% of Healthcare Services
Margin
3.1% net margin
more than 61% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 2.3 days to cover · settled 2026-09-30
more than 52% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PNTG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+73.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PNTG: institutional holders (13F)
13F holdings, latest reported quarter
2,959,141 sh
$109.3M
1,870,178 sh
$69.1M
1,714,462 sh
$63.3M
1,480,881 sh
$54.7M
1,402,800 sh
$51.8M
Congress trades in PNTG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PNTG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Cheney Kirk Sterling
Filed 2026-08-06
$53.7K
Guerisoli Brent
Filed 2026-08-06
$165.1K
Steik Jason Paul
Filed 2026-08-06
$53.7K
Guerisoli Brent
Filed 2026-07-10
$131.3K
Guerisoli Brent
Filed 2026-07-07
$128.2K
PNTG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
GRANDEUR PEAK GLOBAL MICROCAP FUND
$1.6M position · as of 2026-07-31
3.7%
Paradigm Micro-Cap Fund
$6.7M position · as of 2026-06-30
3.6%
Ranger Micro Cap Fund
$407.0K position · as of 2026-07-31
3.5%
Victory RS Investors Fund
$2.3M position · as of 2026-06-30
3.2%
Wasatch Micro Cap Fund
$17.9M position · as of 2026-06-30
2.7%
Wasatch Long/Short Alpha Fund
$887.8K position · as of 2026-06-30
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Brent J. Guerisoli
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.7M
$3.0M
$2.4M
-52%
-2%
2024
$2.6M
$4.5M
$1.4M
-54%
-5%
2023
$1.9M
$2.4M
$820.7K
-76%
-4%
2022
$1.6M
n/a
$828.1K
-81%
-18%
2021
$348.7K
-$41.4M
$601.7K
-60%
-2%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $690.1K sold by insiders over 180 days, 102 funds added last quarter, $272.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PNTG financials
Revenue growth
+36.3%
XBRL, annual
Net margin
3.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PNTG
| FY Dec 2025 | $947.7M |
| FY Dec 2024 | $695.2M |
| FY Dec 2023 | $544.9M |
| FY Dec 2022 | $473.2M |
| FY Dec 2021 | $439.7M |
| Jun 2026 | $298.0M |
| Mar 2026 | $285.4M |
| Dec 2025 | $289.3M |
| Sep 2025 | $229.0M |
| Jun 2025 | $219.5M |
| Mar 2025 | $209.8M |
| Dec 2024 | $188.9M |
| Sep 2024 | $180.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PNTG
| FY Dec 2025 | +3.1% |
| FY Dec 2024 | +3.2% |
| FY Dec 2023 | +2.5% |
| FY Dec 2022 | +1.4% |
| FY Dec 2021 | +0.6% |
| Jun 2026 | +3.0% |
| Mar 2026 | +3.0% |
| Dec 2025 | +3.0% |
| Sep 2025 | +2.7% |
| Jun 2025 | +3.2% |
| Mar 2025 | +3.7% |
| Dec 2024 | +3.0% |
| Sep 2024 | +3.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$34.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PNTG
| FY Dec 2025 | $36.3M |
| FY Dec 2024 | $30.3M |
| FY Dec 2023 | $25.0M |
| FY Dec 2022 | -$5.1M |
| FY Dec 2021 | -$24.5M |
| Jun 2026 | $15.5M |
| Mar 2026 | -$8.7M |
| Dec 2025 | $17.4M |
| Sep 2025 | $10.5M |
| Jun 2025 | $31.6M |
| Mar 2025 | -$23.2M |
| Dec 2024 | $17.2M |
| Sep 2024 | $6.8M |
At each fiscal year end
Single quarter
Debt to equity
0.48x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity PNTG
| FY Dec 2025 | 0.45x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.44x |
| FY Dec 2022 | 0.50x |
| FY Dec 2021 | 0.45x |
| Jun 2026 | 0.48x |
| Mar 2026 | 0.42x |
| Dec 2025 | 0.45x |
| Sep 2025 | 0.08x |
| Jun 2025 | 0.11x |
| Mar 2025 | 0.16x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.28x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt PNTG
| FY Dec 2025 | 0.29x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.52x |
| FY Dec 2022 | 0.14x |
| FY Dec 2021 | -0.35x |
| Jun 2026 | 0.28x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.29x |
| Sep 2025 | 1.84x |
| Jun 2025 | 1.13x |
| Mar 2025 | 0.33x |
| Dec 2024 | n/a |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+8.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PNTG
| FY Dec 2025 | +8.6% |
| FY Dec 2024 | +9.9% |
| FY Dec 2023 | +9.9% |
| FY Dec 2022 | +5.5% |
| FY Dec 2021 | +2.5% |
| Jun 2026 | +8.8% |
| Mar 2026 | +8.5% |
| Dec 2025 | +8.6% |
| Sep 2025 | +10.1% |
| Jun 2025 | +10.6% |
| Mar 2025 | +10.4% |
| Dec 2024 | +9.9% |
| Sep 2024 | +12.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PNTG
| FY Dec 2025 | +3.6% |
| FY Dec 2024 | +3.7% |
| FY Dec 2023 | +2.5% |
| FY Dec 2022 | +1.3% |
| FY Dec 2021 | +0.5% |
| Jun 2026 | +3.6% |
| Mar 2026 | +3.6% |
| Dec 2025 | +3.6% |
| Sep 2025 | +3.8% |
| Jun 2025 | +4.0% |
| Mar 2025 | +3.8% |
| Dec 2024 | +3.7% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+8.1%
operating income after a 26.9% effective tax rate, over LongTermDebt as filed 2026-06-30 (includes the current portion) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PNTG
| FY Dec 2025 | +7.5% |
| FY Dec 2024 | +12.9% |
| FY Dec 2023 | +9.0% |
| FY Dec 2022 | +5.7% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | +8.1% |
| Mar 2026 | +8.0% |
| Dec 2025 | +7.5% |
| Sep 2025 | +11.2% |
| Jun 2025 | +11.7% |
| Mar 2025 | +11.0% |
| Dec 2024 | +12.9% |
| Sep 2024 | +10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PNTG
| FY Dec 2025 | +7.4% |
| FY Dec 2024 | +7.3% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | +2.8% |
| FY Dec 2021 | +1.1% |
| Jun 2026 | +8.1% |
| Mar 2026 | +7.6% |
| Dec 2025 | +7.4% |
| Sep 2025 | +7.3% |
| Jun 2025 | +7.6% |
| Mar 2025 | +7.3% |
| Dec 2024 | +7.3% |
| Sep 2024 | +7.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
46.78x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PNTG
| FY Dec 2025 | 33.51x |
| FY Dec 2024 | 37.89x |
| FY Dec 2023 | 31.64x |
| FY Dec 2022 | 49.91x |
| FY Dec 2021 | 256.44x |
| Jun 2026 | 40.60x |
| Mar 2026 | 35.44x |
| Dec 2025 | 33.51x |
| Sep 2025 | 33.63x |
| Jun 2025 | 38.27x |
| Mar 2025 | 33.09x |
| Dec 2024 | 37.89x |
| Sep 2024 | 52.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no cash line filed
Enterprise value PNTG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield PNTG
| FY Dec 2025 | +3.7% |
| FY Dec 2024 | +3.3% |
| FY Dec 2023 | +6.0% |
| FY Dec 2022 | -1.6% |
| FY Dec 2021 | -3.7% |
| Jun 2026 | +2.7% |
| Mar 2026 | +4.8% |
| Dec 2025 | +3.7% |
| Sep 2025 | +4.1% |
| Jun 2025 | +3.2% |
| Mar 2025 | +1.1% |
| Dec 2024 | +3.3% |
| Sep 2024 | +1.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
2.81x
P/E over trailing EPS growth of 17%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PNTG
| FY Dec 2025 | 1.68x |
| FY Dec 2024 | 0.64x |
| FY Dec 2023 | 0.32x |
| FY Dec 2022 | 0.35x |
| FY Dec 2021 | n/a |
| Jun 2026 | 2.44x |
| Mar 2026 | 2.69x |
| Dec 2025 | 1.68x |
| Sep 2025 | 3.27x |
| Jun 2025 | 1.61x |
| Mar 2025 | 0.81x |
| Dec 2024 | 0.64x |
| Sep 2024 | 0.85x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $947.7M | $695.2M | $544.9M | $473.2M |
| Operating income | $51.9M | $38.1M | $25.2M | $12.7M |
| Net income | $29.6M | $22.6M | $13.4M | $6.6M |
| EPS (diluted) | 0.84 | 0.70 | 0.44 | 0.22 |
| Operating cash flow | $48.3M | $39.3M | $33.1M | $9.0M |
| Long-term debt | $168.8M | $0 | $63.9M | $62.9M |
| Buybacks | n/a | n/a | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
PNTG Stock Sonar score 6/7 axes
Find similar shapesComparePNTG ranks highest on growth (85th percentile) and risk and compliance (59th), and lowest on insider conviction (28th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PNTG filings, in plain words
Are Pennant insiders buying or selling PNTG?
In the 180 days to 2026-10-28, Pennant insiders were net sellers, a net $690.1K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of PNTG?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $272.4K of stock; the latest, by Cheney Kirk Sterling, was filed 2026-08-06.
Read the full summary
In the 180 days to 2026-10-28, Pennant insiders were net sellers of PNTG, a net $690.1K across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $272.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
